TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02322307

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HealthPROMISE users
Description: Patients using HealthPROMISE will be asked to use the application once every two weeks at a minimum to provide updates on health information. Providers can use the data entered by patients in real time. Patients will get alerts requesting them to contact their providers if their quality of life scores fall below a certain threshold or their symptoms scores are worrisome. Both patients and physicians are also sent regular notifications with data about their own health or health of their patient panel respectively. Both patients and providers are encouraged to use existing communication tools (phone, office visits, personal health records) since direct patient-physician messaging is not provided in the HealthPROMISE platform. Reminders through app, email and SMS will be used to facilitate patient engagement.~Physicians will also be encouraged to check the physician panel to see how patients are doing through weekly updates and monthly quality improvement meetings.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: In order to eliminate a placebo effect, patients in both groups will get an app customized for IBD. Physician and rest of care team will not be blinded since they will use HealthPROMISE dashboard to get alerts and notifications.
Study: NCT03626467

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV9v
Description: Single-arm, phase 4 study. Patients will be treated with HPV9v vaccine at baseline, week 8 and week 24
Study: NCT02280005

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WAK Treatment
Description: Hemodialysis with WAK device.
Study: NCT00772460

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patient Warming with conductive / convective warming
Description: Warming device set to maximum (43 °C)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Patient Warming with conductive / convective warming
Description: Warming device set to maximum (43 °C)
Study: NCT00974233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: 90 mg/m2/day IV days 1 and 2 every 28 days for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 Day 1 every 28 days for 6 cycles
Study: NCT02471404

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: 10 mg, orally Green, plain, diamond-shaped, film-coated tablet
Study: NCT00974233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 5 mg/day days 1-28 of each 28 day cycle, up to 12 cycles maximum. Dose escalation to 10 mg/day allowed after one cycle as defined in the protocol.
Study: NCT02471404

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: 10 mg, orally Green, plain, diamond-shaped, film-coated tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saxagliptin
Description: 5 mg, orally Plain, yellow, biconvex, round, film-coated tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: 1, 2, or 4 mg, orally Opaque gray capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for dapagliflozin
Description: Does not contain active ingredient, orally Green, plain, diamond-shaped, film-coated tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for saxagliptin
Description: Does not contain active ingredient, orally Plain, yellow, biconvex, round, film-coated tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for saxagliptin
Description: Does not contain active ingredient, orally Plain, yellow, biconvex, round, film-coated tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for glimepiride
Description: Does not contain active ingredient, orally. Opaque gray capsule
Study: NCT00100477

Intervention type: DRUG
Group type: OTHER
Intervention: Topotecan

Intervention type: DRUG
Group type: OTHER
Intervention: Mitozantrone

Intervention type: DRUG
Group type: OTHER
Intervention: Etoposide
Study: NCT02471404

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for glimepiride
Description: Does not contain active ingredient, orally. Opaque gray capsule
Study: NCT00658671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENMD-2076
Description: Capsules, daily dosing in 28 day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENMD-2076
Description: Capsules, daily dosing in 28 day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENMD-2076
Description: Capsules, daily dosing in 28 day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENMD-2076
Description: Capsules, daily dosing in 28 day cycles
Study: NCT01566838

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Subpleural pain catheter with infusion of 0.125% bupivacaine
Description: Patients in this arm will be provided with a subpleural pain catheter and instructions for removal when pump is empty (around 5 days time). The catheter will contain an infusion of 0.125% bupivacaine. The single lumen pain catheter is infused by a self deflating pump filled to 335ml, which delivers the infusate at a rate of 4ml/h. Pumps are expected to be empty in 4 to 5 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard acute pain management
Description: A standard balanced anesthetic consisting of midazolam 0.01-0.03mg/kg, induced with propofol (1-2mg/kg) or etomidate, fentanyl (1-2 mcg/kg) and rocuronium (0.1mg/kg) and a potent inhalation agent (sevoflurane 1.5%-2.5%) during procedures.~Prior to emergence from anesthesia, patients will receive ketorolac 30mg IV, neuromuscular reversal agents, and ondansetron 4mg. Fentanyl will be given, as needed, to facilitate patient comfort and extubation.~The ASA guidelines for acute pain management in the perioperative period will be followed. Patients shall receive 1,000 mg of acetaminophen orally every 6 hours, scheduled for 5 days. Other drugs will be given on as needed basis (PRN) to maintain an analog pain scale of ≤ 3.
Study: NCT01415960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate 22.5 mg depot, GP-Pharm SA
Description: Administered by im injection, twice during the study, three months apart
Study: NCT00660140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study: NCT00669773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adriamycin
Description: Arm A: 4 cycles of adriamycin at 75mg/m2 3 weekly followed by surgery followed by 4 cycles of docetaxel at 75mg/m2 3 weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Arm B: 4 cycles of docetaxel at 75mg/m2 3 weekly followed by surgery followed by 4 cycles of adriamycin at 75mg/m2 3 weekly.
Study: NCT02953457

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Given IV
Study: NCT01671774

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IMAB362
Description: 800 mg/m2 on d 1 of cycle 1. 600 mg/m2 on d 1 of every other cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMAB362
Description: 800 mg/m2 on d 1 of cycle 1. 600 mg/m2 on d 1 of every other cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMAB362
Description: 800 mg/m2 on d 1 of cycle 1. 600 mg/m2 on d 1 of every other cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMAB362
Description: 800 mg/m2 on d 1 of cycle 1. 600 mg/m2 on d 1 of every other cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: 4 mg on d 1 of cycle 1 and cycle 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: 4 mg on d 1 of cycle 1 and cycle 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: 4 mg on d 1 of cycle 1 and cycle 3
Study: NCT00436670

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMG 317 75 mg
Description: 75 mg SC weekly injection
Study: NCT01671774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2 (1 million IU)
Description: 1 million IU on day 1, 2 and 3 of cycles 1 and 3.
Study: NCT00436670

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMG 317 150 mg
Description: 150 mg SC once weekly injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMG 317 300 mg
Description: 300 mg weekly SC injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo SC once weekly injection
Study: NCT03211078

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: super-D ENB guided-PDT
Description: PDT with super-D EBN localization will be given for treating the target lung lesion. Intrvenous photofrin (2mg/kg) will be given 48 hours before intervention. After localization of the tumor by ENB, a 630nm of light will be give for the lesion with the dosage of 2oo J/cm. Intravenous general anesthesia and endobronchial intubation will be performed under the whole procedure.
Study: NCT03029962

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Girl2Girl
Description: Girl2Girl is a text messaging-based teenage pregnancy prevention program specifically for 14-18 year old LGB adolescent females. Content is guided by the Information-Motivation-Behavioral Skills (IMB) model and focuses on: HIV information, motivations to engage in HIV preventive behavior, communication skills, behavioral skills (e.g., using a condom; HIV testing); and healthy/unhealthy relationships. Behavioral skills content is reinforced using brief online videos. The intervention is 7 weeks long. A booster is delivered 12-weeks post-intervention end and reviews the topics covered in the intervention. Girl2Girl content is tailored based upon sexual experience (i.e., whether one is abstinent or sexually active) and whether one is same-sex or dually attracted.
Study: NCT04740866

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvant Radiotherapy
Description: Irradiation of both the bladder tumor bed and pelvic lymph nodes using Intensity-Modulated Radiation-Therapy (IMRT) technique. (\[50Gy in 25 fractions conventional fractionation including tumor bed \& pelvic lymph nodes\]
Study: NCT01671774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2 (3 million IU)
Description: 3 million IU on day 1, 2 and 3 of cycles 1 and 3.
Study: NCT01525394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 32 mg will be administered orally as three 4 mg and two 10 mg capsules as a single dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin 400 mg
Description: Moxifloxacin 400 mg will be administered orally as one 400 mg tablet.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos (matched to 4 mg and 10 mg lenvatinib capsules).
Description: The Placebo dose will consist of three 4 mg and two 10 mg placebo capsules.
Study: NCT03210285

Intervention type: DIAGNOSTIC_TEST
Intervention: Whole exome sequencing
Description: Whole exome sequencing

Intervention type: DIAGNOSTIC_TEST
Intervention: Whole exome sequencing
Description: Whole exome sequencing
Study: NCT03177577

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Splint
Description: Subjects will use a splint custom-made by Massachusetts General Hospital Occupational Therapists as part of standard care for treatment of carpometacarpal (CMC) osteoarthritis.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Splint with strengthening exercises
Description: Subjects will use a splint custom-made by Massachusetts General Hospital Occupational Therapists as part of standard care for treatment of carpometacarpal (CMC) osteoarthritis and will also be taught two first dorsal interosseous (FDI) strengthening exercises.
Study: NCT00875420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD1901
Description: 10 mg Oral once a day for 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD1901
Description: 25 mg Oral once a day for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD1901
Description: 50 mg Oral once a day for 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD1901
Description: 100 mg Oral once a day for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Oral once a day for 28 days
Study: NCT04097288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram 40mg
Description: Single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reboxetine 8 mg
Description: Single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Single dose
Study: NCT02114203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDE9i
Description: oral dose, every 12 hours for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDE9i
Description: oral dose, every 12 hours for 28 days
Study: NCT04013217

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Eribulin ORA
Description: Oral eribulin mesylate will be supplied as an aqueous solution and HM30181A-UK
Study: NCT02319655

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Air tamponade
Description: Air tamponade

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Balanced salt solution filling
Description: BSS filling
Study: NCT02462681

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paravertebral block
Description: Thoracic paravertebral blocks will be performed as described by Moore and Katz. Intradermal lidocaine will be used at the site of the needle insertion. The superior aspect of the spinous processes of T1- T6 will be marked. The skin entry points will 3 cm laterals to the marks. A 22- gauge quincke spinal needle attach to extension tubing to a syringe containing study drugs will be used. The needle will be inserted perpendicular to the skin for a distance of 2 to 4 cm until the transverse process will contact. The needle will be withdrawn and walk cephalad off the transverse process and advance for a further 1.5 to 2 cm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paravertebral block
Description: Thoracic paravertebral blocks will be performed as described by Moore and Katz. Intradermal lidocaine will be used at the site of the needle insertion. The superior aspect of the spinous processes of T1- T6 will be marked. The skin entry points will 3 cm laterals to the marks. A 22- gauge quincke spinal needle attach to extension tubing to a syringe containing study drugs will be used. The needle will be inserted perpendicular to the skin for a distance of 2 to 4 cm until the transverse process will contact. The needle will be withdrawn and walk cephalad off the transverse process and advance for a further 1.5 to 2 cm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paravertebral block
Description: Thoracic paravertebral blocks will be performed as described by Moore and Katz. Intradermal lidocaine will be used at the site of the needle insertion. The superior aspect of the spinous processes of T1- T6 will be marked. The skin entry points will 3 cm laterals to the marks. A 22- gauge quincke spinal needle attach to extension tubing to a syringe containing study drugs will be used. The needle will be inserted perpendicular to the skin for a distance of 2 to 4 cm until the transverse process will contact. The needle will be withdrawn and walk cephalad off the transverse process and advance for a further 1.5 to 2 cm.
Study: NCT02730650

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Platelet Rich Therapy (PRT)
Description: Platelet Rich Therapy (PRT) involves injection of patient's own platelets and fibrin.Topical anesthetic will be applied to the face for a period of fifteen minutes prior to the injection. For PRP preparation, 8 cc of blood will be collected from each patient just before each procedure. Approximately 0.3-0.4 cc of PRP will be injected into each standardized injection point in a superficial manner. The injections points are 6 points on each side of the face along the inferior border of cheek and mid-cheek (12 total). The PRP injection will be followed by 10-15 minutes of icing.
Study: NCT04690985

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary behaviour change
Description: The intervention consists of dietary guidance and behaviour change techniques, which will last for 15 weeks. The experimental group will be required to adhere to a diet consisting of a 12% reduction in calorie and a 1.2-1.5 g/kg body weight/day intake of protein. The participants will receive the dietary behaviour change guidance in 6 times face-to-face meetings and weekly telephone calls. They will also be asked to take daily food diary.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Social contact
Description: The control group will not be required any dietary changes. The investigator will contact with the control group with the same frequency and numbers of experimental group. But the chat topic will not be related to sarcopenic obesity or dietary guidance.
Study: NCT01299662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly ICLC
Description: One 1.6 mg subcutaneous injection of the study drug, poly ICLC in the upper arm.
Study: NCT03060486

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HYBENX®
Description: The mixture was then introduced inside the root canal using the pre-dosed syringe for 20 seconds with a sterile paper point with and up and down movement.~Finally, the canal was rinsed with sterile saline water using a syringe with a side-vented 30 G needle.
Study: NCT00471510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tetrapeptide aldehyde proteasome inhibitor (NEOSH101)
Description: Study preparation (experimental, placebo comparator) will be applied to the scalp once daily for 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tetrapeptide aldehyde proteasome inhibitor (NEOSH101)
Description: Study preparation (experimental, placebo comparator) will be applied to the scalp once daily for 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tetrapeptide aldehyde proteasome inhibitor (NEOSH101)
Description: Study preparation (experimental, placebo comparator) will be applied to the scalp once daily for 16 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: tetrapeptide aldehyde proteasome inhibitor (NEOSH101)
Description: Study preparation (experimental, placebo comparator) will be applied to the scalp once daily for 16 weeks
Study: NCT04056338

Intervention type: OTHER
Intervention: No intervention
Description: No intervention.
Study: NCT02336087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel Albumin-Stabilized Nanoparticle Formulation
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride
Description: Given PO

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Therapeutic Dietary Intervention
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT00902538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil 40 mg - Amlodipine 10 mg
Description: Oral tablets containing Olmesartan medoxomil-Amlodipine 40-10 mg, given once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olmesartan 40mg-Amlodipine 10mg-Hydrochlorothiazide 12.5mg
Description: Coated, oral tablets containing Olmesartan 40mg-Amlodipine 10mg + 1 Hydrochlorothiazide 12.5mg oral tablet + 1 Hydrochlorothiazide 12.5mg oral, placebo tablet. All tablets are given once a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olmesartan 40mg-Amlodipine 10mg-Hydrochlorothiazide 25mg
Description: Coated, oral tablets containing Olmesartan 40mg-Amlodipine 10mg + 2 Hydrochlorothiazide 12.5mg oral tablets. All tablets are given once a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OLM 40mg-AML 10mg-Hydrochlorothiazide 12.5mg
Description: Coated, oral tablets containing Olmesartan 40mg-Amlodipine 10mg + 1 Hydrochlorothiazide 12.5mg oral tablet + 1 Hydrochlorothiazide 12.5mg oral, placebo tablet. All tablets are given once a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OLM 40mg-AML 10mg-Hydrochlorothiazide 12.5mg
Description: Coated, oral tablets containing Olmesartan 40mg-Amlodipine 10mg + 1 Hydrochlorothiazide 12.5mg oral tablet + 1 Hydrochlorothiazide 12.5mg oral, placebo tablet. All tablets are given once a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OLM 40mg-AML 10mg-Hydrochlorothiazide 25mg
Description: Coated, oral tablets containing Olmesartan 40mg-Amlodipine 10mg + 2 Hydrochlorothiazide 12.5mg oral tablet. All tablets are given once a day.
Study: NCT03260686

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: experimental
Description: video guide for upper limb exercise
Study: NCT01851772

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment with Electronic Brachytherapy
Study: NCT00484679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide 10 mg/mL (Kenalog-10)
Description: Triamcinolone Acetonide 10 mg/ml (Kenalog-10) intralesional injection
Study: NCT03448094

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resveratrol
Description: Participants will consume one of the treatment types daily for a period of three months.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will consume one of the treatment types daily for a period of three months.
Study: NCT02179294

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pethidine
Description: 100mg by intramuscular injection, up to 4 hourly in frequency (up to a maximum of 4 doses). The maximum dose being 400mg in 24 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Dedicated intravenous cannula for remifentanil administration PCA protocol~* PCA bolus remifentanil 40 μg~* Lockout interval 2 minutes~In the event of excess sedation being recorded by regular observation of respiratory function, the regimen will be altered by reduction of the remifentanil bolus dose to 30 μg with a lock-out interval of 2 minutes.